Variable | Sample n = 1033 (100 %) | Population n = 9658 (100 %) | Male n = 316 (30.6 %) | Female n = 717 (69.4 %) | p value comparison between males and females |
---|---|---|---|---|---|
Sex (females), n (%) | 717 (69.4 %) | 6896 (71.4 %) | – | – |  |
Age (years), median (IQR) | 42 (36–50) | 40 (37–53) | 46 (39–53) | 41 (35–48) | <0.001 |
Age category (years) | |||||
 18–≤35 (n,  %) | 242 (23.5) | 1565 (16.2) | 51 (16.2) | 191 (26.7) | <0.001 |
 35–≤45 | 406 (39.5) | 3390 (35.1) | 104 (33.1) | 302 (42.4) | |
 45–≤55 | 247 (24.0) | 3100 (32.1) | 94 (29.9) | 153 (21.4) | |
 >55* | 134 (13.0) | 1603 (16.6) | 65 (20.7) | 69 (9.7) | |
Baseline CD4 + cell count (cells/mL), median (IQR) | 191 (104–310) | 184 (85–279) | 174 (95–269) | 202 (108–312) | 0.023 |
Baseline CD4+ cell count below 350 cells/mL number (%) | 685 (84.6) | 8654 (89.6) | 212 (87.2) | 473 (83.3) | 0.153 |
Baseline WHO HIV clinical stage III–IV number (%) | 451 (50.8) | 5360 (55.5) | 156 (55.5) | 295 (48.8) | 0.013 |
Duration since HIV seropositive state (years), median (IQR) | 7.1 (5.4–9.2) | 6.9 (5.0–9.1) | 6.7 (5.1–9.3) | 7.4 (5.5–9.2) | 0.073 |
Duration of ART exposure (years), median (IQR) | 5.3 (3.4–7.1) | 5.3 (2.9–6.9) | 5.2 (2.8–7.0) | 5.4 (3.7–7.2) | 0.234 |
Duration ART exposure (categorical) (years) | |||||
 <2, number (%): | 182 (18.2) | 1729 (17.9) | 65 (21.1) | 117 (16.8) | 0.269 |
 2–5 | 262 (26.1) | 2501 (25.9) | 77 (25.0) | 185 (26.6) | |
 >5 | 559 (55.7) | 5302 (54.9) | 166 (53.9) | 393 (56.6) | |
ART regimen frequencies, (number, Â %) | |||||
 PI-based | 48 (4.7) | 425 (4.4) | 17 (5.4) | 31 (4.3) | 0.001 |
 D4T/3TC + EFV or NVP | 624 (60.4) | 5766 (59.7) | 212 (67.1) | 412 (57.5) | |
 TDF/3TC + EFV or NVP | 246 (23.8) | 2115 (21.9) | 56 (16.1) | 190 (26.5) | |
 AZT/3TC + EFV or NVP | 115 (11.1) | 1043 (10.8) | 31 (9.8) | 84 (11.7) |